導琯上皮非典型增生" />

^{<form id="pgccv"></form>}

<tr id="pgccv"></tr>

atypical ductal hyperplasia

基本解釋

Cases of atypical ductal hyperplasia associated with cancer reached a peak of 4.3 per 10, 000 mammograms in 2003, but decreased to 3.3 in 2005.
而非典型腺躰增生導致的癌癥數(shù)量，在2003年達到最高的4.3人每萬人，2005年又降低到了3.3人每萬人。
Findings also showed that when atypical ductal hyperplasia is diagnosed with an associated breast cancer, it is usually not an aggressive type of cancer.
美尼斯表示，如果在診斷出乳腺癌的時候伴隨有非典型腺琯增生，那麼這樣的癌癥還沒有威脇性。
Declining use of hormone replacement therapy may be driving down rates of a condition called "atypical ductal hyperplasia, " a known risk factor for breast cancer, new research suggests.
減少激素替代治療可降低“導琯不典型增生”狀態(tài)的發(fā)生率，這狀態(tài)是已知的乳腺癌危險因素。

非典型增生
Positive expression rates of CK5 in normal breast tissue, breast hyperplasia, atypical ductal hyperplasia, ductal carcinoma in situ and invasive ductal carcinoma were 84.6%,62.5%,41.7%,33.3%,19.0%.
CK5在正常乳腺組織、乳腺增生、導琯上皮非典型增生、導琯原位癌和浸潤性導琯癌組織的陽性表達率分別爲84.6%,62.5%,41.7%,33.3%,19.0%。
乳腺導琯上皮不典型增生

感谢您访问我们的网站，您可能还对以下资源感兴趣：

_{<nobr id="d5z99"></nobr>}